- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01785459
Bupivacaine for Benign Headache in the ED
Treatment of Benign Headache in the Emergency Department Population With Lower Cervical Paraspinous Bupivacaine Injections Versus Anti-Emetic Treatment in the Emergency Department Population: Randomized Prospective Control Trial
Headache is a common chief complaint of patients presenting to the emergency department (ED), accounting for approximately 3 million ED visits per year. Headache treatment is often a source of frustration for both patients and providers. By the time patients with benign headaches arrive in the emergency department, they have often failed non-invasive therapeutic attempts and providers are often left with few therapeutic options. Treatment of benign headache varies between providers, often including systemic medications with a multitude of possible side effects. In recent years, there has been preliminary investigation into anesthetic injections for the undifferentiated headache patient presenting to the emergency department. It has been proposed that these patients presenting with benign headache might benefit from this novel treatment.
Patients that present to the Emergency Department with a diagnosis of benign or primary headache with serious or life-threatening causes of headache will be offered enrollment into the study.
Following consent, subjects will receive either 0.5% bupivacaine injected bilaterally in the paraspinal musculature of the cervical spine or the standard treatment with intravenous Prochlorperazine. The subjects will complete a validated pain scale before, and 20 minutes after injection. At twenty minutes post-injection, the subject will be reevaluated for symptoms. The subject will then be eligible for discharge or standard treatment at the discretion of the treating physician.
Subjects will be followed for 72 hours after enrollment for headache recurrence. Subjects will be monitored for immediate and post-discharge complications.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Headache is a common chief complaint of patients presenting to the emergency department (ED), accounting for approximately 3 million ED visits per year. Headache treatment is often a source of frustration for both patients and providers. By the time patients with benign headaches arrive in the emergency department, they have often failed non-invasive therapeutic attempts and providers are often left with few therapeutic options. Treatment of benign headache varies between providers, often including systemic medications with a multitude of possible side effects. Additionally, most headache cocktails require prolonged duration of treatment, occupying valuable bed space in increasingly busy emergency departments.
In recent years, there has been preliminary investigation into anesthetic injections for the undifferentiated headache patient presenting to the emergency department. It has been proposed that these patients presenting with benign headache might benefit from this novel treatment. Since 2003, paraspinal muscle injections of bupivacaine have been used in emergency department patients with encouraging results. The mechanism of action is not clearly understood; however, it has been proposed that these injections affect the trigeminocervical complex hypothesized to play an integral role in headache physiology, similar to the same mechanism behind greater occipital nerve blocks used by neurologists.
To the best of the investigators knowledge, there has never been a prospective double-blinded randomized control trial addressing this novel approach to headache management. Even so, the topic of using bupivacaine to inject the paraspinal musculature of the cervical spine has gained wider recognition over the past year. The topic has been discussed heavily on emergency medicine blogs and podcasts. Additionally, online videos have been posted to educate emergency medicine providers on the injection technique. According to retrospective literature, clinical efficacy was observed with a significant proportion of the patients receiving therapeutic effect. These studies, along with anecdotal experience with the procedure at the investigators institution, have led to great excitement concerning the possibility of a new approach to emergency department headache management. However, the topic still needs investigation with a well-designed prospective clinical trial to determine true clinical utility.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28203
- Carolinas Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-65 years old
- Diagnosis of benign or primary headache
Exclusion Criteria:
- Hypersensitivity or allergy to bupivacaine (amide anesthetics) or prochlorperazine or other drugs in the same class, dopaminergic blockers.
- Overlying signs of infection at site of injection (Erythema, purulence, open skin)
- Neck pathology ( History of surgery to the cervical spine, History of surgical hardware in place, Documented disc abnormality, History of vertebral artery or carotid artery dissection, Torticollis)
- Intracranial abnormality/pathology (Tumor, Hemorrhage, Concussion or post concussive syndrome)
- History of increased intracranial pressure (ICP)
- A known history of extrapyramidal symptoms, dystonia, parkinsonism, tardive dyskinesia or neuroleptic malignant syndrome
- Known pregnancy
- Narcotic seeking patients as determined by the treating physician with optional assistance from medical record review and North Carolina Drug Database
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: standard care
intravenous Prochlorperazine
|
10 mg Intravenous injection of Prochlorperazine
Other Names:
|
Experimental: treatment
0.5% bupivacaine
|
The injection site will be prepared using common sterile technique with 2% chlorhexidine.
1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.
Location would be approximately 1 cm superior to spinous process of C7 and approximately 2-3 cm laterally.
The needle is inserted 1 to 1.5 inches into the paraspinous musculature at this level.
A 27-gauge needle would be used to minimize tissue trauma and pain to the patient.
Our method of injection is followed quite closely with the technique depicted in multiple retrospective studies.
We chose to follow previous reported technique secondary to good clinical efficacy and impressive documented safety profile.
Additionally, before injection, aspiration would be performed to lesson chance of intravascular injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Length of Stay
Time Frame: enrollment day
|
Length of stay will be calculated as total time of encounter as well as time from doctor encounter to disposition decision
|
enrollment day
|
Incidence of Immediate and Post-discharge Complications.
Time Frame: 72 hours
|
Subjects will be monitored for both immediate and post discharge complications up to 72 hours after enrollment that include: persistent local pain, bleeding, infection, and inadvertent intravascular injection resulting in seizure or possible cardiovascular collapse.
|
72 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptomatic Relief of Headache
Time Frame: 20 minutes
|
Symptomatic relief of headache will be measured by:
|
20 minutes
|
Collaborators and Investigators
Investigators
- Principal Investigator: Sean Fox, MD, Carolinas Medical Center
- Principal Investigator: Carey Nichols, MD, Carolinas Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Headache
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Antiemetics
- Gastrointestinal Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Dopamine Agents
- Dopamine Antagonists
- Anesthetics, Local
- Bupivacaine
- Prochlorperazine
Other Study ID Numbers
- BBH-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Benign Headache
-
Cynosure, Inc.CompletedBenign Pigmented Lesions | Wrinkle | Benign Vascular LesionsUnited States
-
Anadolu Medical CenterCompletedMigraine | Positional Vertigo
-
National Cancer Institute (NCI)RecruitingCancer | Tumor | Benign Neoplasms | Carcinogens | Neoplasm, BenignUnited States
-
Canadian Memorial Chiropractic CollegeDr. Zaxx Co.UnknownMigraine Headache | Cervicogenic Headache | Tension-type HeadacheCanada
-
University of Illinois at ChicagoGlaxoSmithKlineCompletedBenign Prostate TissueUnited States
-
Syneron MedicalUnknownBenign Pigmented LesionsUnited States
-
University GhentRecruitingTension-Type Headache | Cervicogenic Headache | Myofascial HeadacheBelgium
-
Real Centro Universitario Maria CristinaRecruiting
-
Brooke Army Medical CenterThe University of Queensland; The Defense and Veterans Brain Injury CenterRecruitingHeadache, Migraine | Persistent Post Traumatic Headache | Cervicogenic HeadacheUnited States
-
Uniformed Services University of the Health SciencesNational Institutes of Health (NIH); University of North Carolina, Chapel Hill and other collaboratorsRecruitingPost-Traumatic Headache Chronic Without Intractable HeadacheUnited States
Clinical Trials on Standard Care
-
Neuroscience Trials AustraliaNational Institute for Health Research, United Kingdom; Northern Ireland Chest... and other collaboratorsCompleted
-
Evandro Chagas Institute of Clinical ResearchAlejandro Marcel Hasslocher Moreno, MD MSc PhD student; Andrea Costa, MD PhD; Andrea Silvestre de Sousa, MD PhD and other collaboratorsUnknownChagas Heart DiseaseBrazil
-
University of OklahomaNational Cancer Institute (NCI)CompletedSmoking CessationUnited States
-
Avita MedicalNAMSACompletedVenous Leg UlcersUnited Kingdom, France
-
University of MichiganCompleted
-
University of OklahomaCompletedTobacco Cessation | Tobacco Use | Tobacco Smoking | Smoking Cessation Financial Incentives | Socioeconomic Status | Contingency ManagementUnited States
-
University of OklahomaEnrolling by invitationTobacco Cessation | Tobacco Use | Tobacco Smoking | Smoking Cessation Financial Incentives | Socioeconomic Status | Contingency Management | PregnancyUnited States
-
Institut de Cancérologie de LorraineTerminatedBreast CancerFrance
-
Indonesia UniversityCompletedCovid19 | AcupunctureIndonesia
-
Johns Hopkins UniversityRecruitingCompartment Syndrome of Leg | Extracorporeal Membrane Oxygenation Complication | Limb Ischemia, Critical | Limb IschemiaUnited States